allel or crossover design. Ten trials studied lidocaine and 9 studied mexiletine. Intervention: Intravenous lidocaine or oral mexiletine. Outcomes: Reduction in neuropathic pain, measured on a continuous scale and reported as the weighted mean difference on a 0-to 100-mm visual analogue scale. Prevalence and severity of side effects were also analyzed. Results: Lidocaine and mexiletine were superior to placebo (weighted mean difference, Ϫ10.60 mm [95% CI, Ϫ14.52 to Ϫ6.68 mm]; P Ͻ 0.001). Separate analyses of studies of lidocaine and mexiletine yielded similar results. Five studies compared the agents with active control; no significant differences were found in pain relief (weighted mean difference, Ϫ0.60 mm [CI, Ϫ6.96 to 5.75 mm]) or adverse events. No serious adverse events were reported in any trial with these agents. Conclusion: Intravenous lidocaine and oral mexiletine seem to be effective and safe treatments for neuropathic pain. Commentary: Neuropathic pain syndromes remain a clinical challenge for internists and pain specialists. This article pools data from randomized trials and supports previous uncontrolled studies (6, 7) demonstrating that intravenous lidocaine and oral mexiletine are a viable choice for treating patients with difficult-to-control neuropathic pain. Several caveats must be considered in interpreting this meta-analysis, however. Cause of pain was the greatest source of heterogeneity in the analysis, and only 6 of the trials included patients with the neuropathic pain syndromes most frequently encountered in palliative medicine (for example, cancer, HIV, stroke, and spinal cord injury). The pain syndromes studied in most of the included trials (painful diabetic neuropathy and postherpetic neuralgia) present less often in palliative care settings. Finally, the clinical significance of an 11-mm change in a visual analogue scale is difficult to interpret. Clinical Bottom Line: Consider using intravenous lidocaine or oral mexiletine for refractory neuropathic pain, although further studies are needed to better define efficacy and to clarify the appropriate place of these agents in treatment algorithms. Question: Is endoscopic stenting as effective as surgical gastroenterostomy for treating malignant gastroduodenal obstruction? Study Design: Meta-analysis. Patients: 307 patients (age range, 64 to 79 years) with gastroduodenal obstruction due to inoperable malignant disease, studied in 1 randomized, controlled trial and 8 retrospective studies. Primary malignant conditions were pancreatic, duodenal, stomach, and bile duct cancer. Intervention: Endoscopic stenting or surgical gastroenterostomy. Outcomes: Clinical success, defined as improved dietary status, adequate gastric emptying, or tolerance of at least a light diet; number of days from procedure to clinical improvement; overall complications; delayed gastric emptying after intervention; length of hospital stay; and 30-day mortality. Results: Pooled data showed that endoscopic stenting was associated with a higher clinical success rate than gastroenterostomy (odds ratio, 2.97 [CI, 1.34 to 6.57]; P ϭ 0.007). Time from procedure to oral intake was 5.4 days shorter for stenting than for surgery (P Ͻ 0.001), but there was significant heterogeneity between studies for this result. Although the overall frequency of complications was less for stenting (17 complications [14%] for stenting vs. 38 complications [31%] for surgery; P ϭ 0.02), the authors did not consider this to be significant because of concerns that selection and publication bias in favor of stenting influenced the result. Stenting reduced the risk for delayed gastric emptying (odds ratio, 0.08 [CI, 0.02 to 0.41]), although not all studies reported the outcome. Length of hospital stay after intervention was 9.7 days shorter (CI, 7.7 to 11.6 days) with stenting. Thirty-day mortality was lower with stenting but did not statistically significantly differ from that with surgery. (8, 9) , so it is important that palliative procedures are effective and not overly burdensome and minimize hospital length of stay. These data demonstrate that stenting of gastroduodenal obstruction confers these advantages better than surgery to relieve the obstruction. However, the studies in the meta-analysis were small, they were subject to publication and language biases, and the clinicians performing the interventions had different levels of expertise. Also, laparoscopic gastrojejunostomy has gained popularity in recent years. Studies of this procedure were not included in the meta-analysis, and laparoscopic procedures may offer a reasonable alternative to open surgery for patients who have an obstruction that cannot be relieved through endoscopic stenting. Clinical Bottom Line: Refer patients with malignant gastroduodenal obstruction to endoscopists experienced in luminal stenting.
Nonpain Symptom Management

Nursing Home Care
Loeb M, Carusone SC, Goeree R, et al. Results were similar in analyses restricted to patients with radiographically defined pneumonia. There were no differences in secondary outcomes. Initially higher costs for patients in the intervention group were offset by reduced professional billings, resident transportation, and hospitalization costs, with an overall cost savings with the intervention of $1016 (Canadian) per resident. In U.S. dollars, the savings were estimated to be $1517 per resident.
Conclusion:
An algorithm for treating nursing home residents with lower respiratory tract infections on site prevents acute hospitalizations and reduces overall health care costs.
Commentary:
The question asked by this study is important because pneumonia and other lower respiratory tract infections occur frequently in nursing home residents (10, 11) . One limitation is that research nurses at the participating institutions were not blinded to the intervention, which may have biased data collection. Another is that the study was undertaken within the single-payer Canadian health care system, so the results are more generalizable to systems where costs are contained within a single-payer structure, such as Kaiser Permanente and Veterans Affairs medical centers, and less generalizable to most other nursing homes in the United States, in which the initially increased costs of on-site treatment may not be offset by later savings. In these facilities, supplemental funding from insurance providers may be needed to implement the pathway and keep residents in the nursing home for treatment.
In addition, the findings may not be generalizable to nursing homes with fewer than 100 beds. Clinical Bottom Line: Consider using the clinical pathway described in this study to treat nursing home patients with lower respiratory tract infection who otherwise resemble study participants. 
Prognosis
Conclusion:
The Seattle Heart Failure model accurately predicts survival of patients with heart failure by using easily available clinical characteristics.
Commentary: Accurate assessment of prognosis helps patients and their families make decisions about treatment and helps clinicians plan patient discharges and referrals to appropriate services, such as hospice. Previous risk models for heart failure have been notoriously inaccurate at predicting prognosis (18) . The Seattle Heart Failure model not only accurately predicts survival but shows changes in prognosis over baseline based on interventions, specifically medications (such as angiotensin-converting enzyme inhibitors) and devices (such as implantable cardioverter defibrillators). However, the model has some limitations. It was developed by using data from outpatients and thus may not be generalizable to inpatients. The statistical derivation of the model uses estimations of hazard ratios for some treatments, which may introduce error into the model predictions. Finally, because the model does not take into account patients' other medical conditions, it may not be generalizable to patients with competing comorbid conditions. Clinical Bottom Line: Use the Seattle Heart Failure model to predict survival in and to counsel patients with heart failure. Commentary: Although this study's findings support the claim that quantity of care does not improve quality of care, the study has important limitations. First, it was retrospective and relied on reports from the deceased patients' family members and friends, who may have inaccurately recalled events. In addition, proxies may not fully appreciate the distress of patients who are near the end of life. Although these data show an association between greater care utilization and lower quality of care, other attributes in these hospital service areas (such as greater fragmentation of care or a predominance of academic medical centers) may contribute to these regional differences. It is reassuring that family members in lower utilization areas did not report more concern about the amount of life-sustaining treatment used, so it does not seem that the use of these treatments in these lower utilization areas was constrained. 
Quality of Care
